Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 27, 2026

Strategy sells $544.5M in MSTR, makes no bitcoin purchase

View original at finance.yahoo.com
Strategy sells $544.5M in MSTR, makes no bitcoin purchase Crypto markets are entering a new phase as institutional adoption accelerates and industry shakeouts continue…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The DTCC settles $4.5 quadrillion in volume a year.

    60% confidence

  • Robinhood's approach to prediction markets resembles a dating app, offering anyone's markets, taking a cut, and moving on.

    60% confidence

  • There are no longer any question marks about Saylor being an irrational actor in the market; the biggest risk to Strategy is duration risk, not price.

    60% confidence

  • Strategy is no longer just a company that raises cash to buy Bitcoin; it now raises cash for many reasons while managing an entire financial ecosystem built around Bitcoin.

    60% confidence

  • The four crypto business shutdowns/bankruptcies in one week are bottom signals for the market, driven by weak, marginal players being squeezed out rather than technology failure.

    60% confidence

  • Circle's purchase of nearly 1,000 IBM blockchain patents is about building a competitive moat for Circle's Arc and payments network.

    60% confidence

Data points we hold from this source

Strategy · strc repurchase value25 USD
Strategy · cash3.75 USD
Strategy · bitcoin cost basis63.7 USD
Strategy · shares sold5.43 millions
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Strategy sells $544.5M in MSTR, makes no bitcoin purchase — Source | Via News | Via News